Biclonal gammopathies manifestations (BGMs) are defined as a clonal proliferation of plasma cells or B-lymphoid progenitors that produces 2 different monoclonal proteins known as M-proteins or paraproteins. The aim of our study is to report and analyses the epidemiological, biological and clinical features of the cases of biclonal gammopathies diagnosed at the Hassan II University Hospital Center (HUHC), Fez during a period of 10 years (2010-2020). Among the 782 cases of gammopathies diagnosed by immunofixation (IF), 28 were shows biclonal gammopathies (3.5%), the sex ratio M/F was 1 and the median age was 63 years. The most frequent isotype was IgG/IgM with a slight predominance of the Kappa light chain. The most common diagnosis was biclonal gammopathy of undetermined significance (BGUS) in 12 patients (42%), followed by 10 cases of multiple myeloma (MM) (35%) and 6 cases of lymphoproliferative syndrome (21%). Although the clinical features are similar to monoclonal gammopathy, dentification of BGMs increases diagnostic precision in our region, in particular for multiple myeloma cases and lymphoproliferative syndrome compared to other studies.

Introduction: Stroke patients with haemorrhagic and ischemic strokes were compared with regard to stroke severity, mortality, and cardiovascular risk factors. Material and Methods: This prospective and descriptive study was done during January 2019 and September 2020. This case-control study was conducted on an overall population of 120 individuals (40 haemorrhagic, 40 ischemic strokes and as the case groups; 40 healthy individuals as the control group). The diagnosis was made by the clinical examination and brain CT scan. Our excluding criteria were a previous history of a cerebrovascular event, history of a recent infectious or inflammatory disease, cancer, autoimmune disorder, haematological disorder, renal or hepatic disease, or use of immune-suppressive or anti-inflammatory drugs in the previous two months. Result: A total of 120 individuals (40 haemorrhagic strokes and 40 ischemic strokes as the case groups; 40 individuals as the control group) were identified during the study follow-up. The increase in MDA in ischemic stroke (ISPs) and Haemorrhagic stroke patients is highly significant (P < 0.001) when compared to control subjects. This indicates that lipid peroxidation is significantly increased in ISPs and the increase in MDA is more in ISPs than haemorrhagic stroke patients (p<0.001). Similarly, nitric oxide levels are also increased in both ISPs and HSPs. GPX levels are decreased significantly in ISPs and HSPs compared to control subjects(p<0.001). Maximum decline in GPX is found in ISPs with HSPs (p<0.001). The Uric acid levels are significantly increased in ISPs and HSPs when compared to control subjects (p<0.003) and the increase is more in ISPs with HSPs (Table 3). The SOD levels are decreased significantly (p<0.05) in ISPs and HSPs when compared to control subjects, whereas its levels are slightly decreased in ISPs with HSPs. Similarly, Catalase levels also decreased in both ISPs and HSPs. Conclusion: Hence, showed a direct positive correlation with infarct size (Ischemic stroke) but less in hemorrhagic stroke when compared with the control group. The antioxidative parameters like Catalase and superoxide dismutase were decreased both ischemic and hemorrhagic stroke when compared with control.